Manufacturers announce data from GATHER1 Phase 3 study for avacincaptad pegol in geographic atrophy secondary to age-related macular degeneration

In this study, avacincaptad pegol, a novel complement C5 inhibitor, reduced geographic atrophy growth at 12 months by 27.38% and 27.81% vs placebo for the 2 mg and 4 mg dose, respectively (p<0.05 for both).

SPS commentary:

Geographic atrophy, the advanced stage of AMD, leads to further irreversible loss of vision. There are currently no FDA or European Medicines Agency approved treatment options. The second Phase 3 clinical trial, GATHER2, is currently underway and if the primary efficacy endpoint is met at 12 months, the company plans to file for registration with the US and European regulatory authorities.

Biospace Inc.